OR WAIT null SECS
September 21, 2020
Roche will gain full rights to Inflazome’s portfolio which includes clinical and preclinical orally available small molecule NLRP3 inhibitors.
September 03, 2020
Risk-based decision-making is impacting all aspects of manufacturing quality from raw material supply to facility inspections.
September 02, 2020
For certain APIs, including semi-synthetic antibiotics, continuous filtration and drying improves productivity and quality.
August 20, 2020
CARBOGEN AMCIS has announced significant investments to increase manufacturing capacity in Switzerland and France.
August 13, 2020
Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery.
July 08, 2020
CordenPharma added a 3000-L solid-phase peptide synthesis vessel to its GMP API facility in Boulder, CO.
May 19, 2020
HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.
May 06, 2020
Quartic.ai and Bright Path Laboratories have agreed to develop an artificial intelligence (AI)-powered continuous manufacturing platform for APIs and other small-molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.
May 02, 2020
Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?
Discovery of carcinogenic nitrosamines in three of the world’s most widely prescribed drugs is driving efforts to better detect, control and prevent their generation in APIs and finished drug products.